Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
Authors
Keywords
-
Journal
Nature Communications
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-29
DOI
10.1038/s41467-019-09358-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted protein degradation and the enzymology of degraders
- (2018) Stewart L Fisher et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Stabilization of protein-protein interactions in drug discovery
- (2017) Sebastian A. Andrei et al. Expert Opinion on Drug Discovery
- Selective degradation of splicing factor CAPERα by anticancer sulfonamides
- (2017) Taisuke Uehara et al. Nature Chemical Biology
- Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
- (2017) Ting Han et al. SCIENCE
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
- (2016) Mary E. Matyskiela et al. NATURE
- Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
- (2016) Georg Petzold et al. NATURE
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
- (2016) Duncan E. Scott et al. NATURE REVIEWS DRUG DISCOVERY
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Can we safely target the WNT pathway?
- (2014) Michael Kahn NATURE REVIEWS DRUG DISCOVERY
- Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
- (2014) Philip P Chamberlain et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Transcriptional Regulation and Its Misregulation in Disease
- (2013) Tong Ihn Lee et al. CELL
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Towards automated crystallographic structure refinement withphenix.refine
- (2012) Pavel V. Afonine et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Wnt Signaling through Inhibition of β-Catenin Degradation in an Intact Axin1 Complex
- (2012) Vivian S.W. Li et al. CELL
- The Fbw7 and BetaTRCP E3 ubiquitin ligases and their roles in tumorigenesis
- (2012) Alan et al. Frontiers in Bioscience-Landmark
- XDS
- (2010) Wolfgang Kabsch ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- electronic Ligand Builder and Optimization Workbench(eLBOW): a tool for ligand coordinate and restraint generation
- (2009) Nigel W. Moriarty et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- MolProbity: all-atom structure validation for macromolecular crystallography
- (2009) Vincent B. Chen et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- RING Domain E3 Ubiquitin Ligases
- (2009) Raymond J. Deshaies et al. Annual Review of Biochemistry
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started